These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 22806681)

  • 21. Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naive patients infected with HCV genotype 1.
    Serfaty L; Forns X; Goeser T; Ferenci P; Nevens F; Carosi G; Drenth JP; Lonjon-Domanec I; DeMasi R; Picchio G; Beumont M; Marcellin P
    Gut; 2012 Oct; 61(10):1473-80. PubMed ID: 22387529
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Virologic characterization of genotype 4 hepatitis C virus variants in patients treated with telaprevir.
    De Meyer S; Ghys A; Dierynck I; Beumont M; Luo D; Picchio G
    Virol J; 2014 May; 11():93. PubMed ID: 24886541
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dynamic changes in HCV RNA levels and viral quasispecies in a patient with chronic hepatitis C after telaprevir-based treatment.
    de Bruijne J; Sullivan JC; Kieffer TL; Botfield M; Shames B; Schinkel J; Molenkamp R; Weegink C; Reesink H
    J Clin Virol; 2012 Feb; 53(2):174-7. PubMed ID: 22138301
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peginterferon alfa-2a and peginterferon alfa-2b combined with ribavirin in patients with genotype 1 chronic hepatitis C: results of a prospective single-centre study.
    Berak H; Laskus T; Kołakowska-Rządzka A; Wasilewski M; Stańczak JJ; Bardadin K; Walewska-Zielecka B; Horban A
    Adv Med Sci; 2014 Sep; 59(2):261-5. PubMed ID: 25117425
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial.
    Sulkowski MS; Bourlière M; Bronowicki JP; Asselah T; Pawlotsky JM; Shafran SD; Pol S; Mauss S; Larrey D; Datsenko Y; Stern JO; Kukolj G; Scherer J; Nehmiz G; Steinmann GG; Böcher WO
    Hepatology; 2013 Jun; 57(6):2155-63. PubMed ID: 23504636
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies.
    Lenz O; Verbinnen T; Fevery B; Tambuyzer L; Vijgen L; Peeters M; Buelens A; Ceulemans H; Beumont M; Picchio G; De Meyer S
    J Hepatol; 2015 May; 62(5):1008-14. PubMed ID: 25445400
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Baseline Polymorphisms and Emergence of Drug Resistance in the NS3/4A Protease of Hepatitis C Virus Genotype 1 following Treatment with Faldaprevir and Pegylated Interferon Alpha 2a/Ribavirin in Phase 2 and Phase 3 Studies.
    Berger KL; Scherer J; Ranga M; Sha N; Stern JO; Quinson AM; Kukolj G
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6017-25. PubMed ID: 26195509
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients.
    Braun DL; Rauch A; Aouri M; Durisch N; Eberhard N; Anagnostopoulos A; Ledergerber B; Müllhaupt B; Metzner KJ; Decosterd L; Böni J; Weber R; Fehr J;
    PLoS One; 2015; 10(7):e0133028. PubMed ID: 26176696
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial.
    Pessôa MG; Cheinquer H; Almeida PR; Silva GF; Lima MP; Paraná R; Lacerda MA; Parise ER; Pernambuco JR; Pedrosa SS; Teixeira R; Sette H; Tatsch F
    Ann Hepatol; 2012; 11(1):52-61. PubMed ID: 22166561
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir.
    McPhee F; Hernandez D; Yu F; Ueland J; Monikowski A; Carifa A; Falk P; Wang C; Fridell R; Eley T; Zhou N; Gardiner D
    Hepatology; 2013 Sep; 58(3):902-11. PubMed ID: 23504694
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Triple therapy with telaprevir: results in hepatitis C virus-genotype 1 infected relapsers and non-responders.
    Forestier N; Zeuzem S
    Liver Int; 2012 Feb; 32 Suppl 1():44-50. PubMed ID: 22212571
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Telaprevir user's guide.
    Liapakis AM; Jacobson I
    Liver Int; 2012 Feb; 32 Suppl 1():17-25. PubMed ID: 22212567
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
    Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M
    Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Retreatment options for patients with chronic hepatitis C].
    Hrstić I; Ostojić R; Vucelić B
    Acta Med Croatica; 2009 Dec; 63(5):417-22. PubMed ID: 20198901
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Telaprevir activity in treatment-naive patients infected hepatitis C virus genotype 4: a randomized trial.
    Benhamou Y; Moussalli J; Ratziu V; Lebray P; De Backer K; De Meyer S; Ghys A; Luo D; Picchio GR; Beumont M
    J Infect Dis; 2013 Sep; 208(6):1000-7. PubMed ID: 23801602
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France.
    Aherfi S; Solas C; Motte A; Moreau J; Borentain P; Mokhtari S; Botta-Fridlund D; Dhiver C; Portal I; Ruiz JM; Ravaux I; Bregigeon S; Poizot-Martin I; Stein A; Gérolami R; Brouqui P; Tamalet C; Colson P
    J Med Virol; 2014 Nov; 86(11):1868-76. PubMed ID: 25052594
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.
    Dore GJ; Lawitz E; Hézode C; Shafran SD; Ramji A; Tatum HA; Taliani G; Tran A; Brunetto MR; Zaltron S; Strasser SI; Weis N; Ghesquiere W; Lee SS; Larrey D; Pol S; Harley H; George J; Fung SK; de Lédinghen V; Hagens P; McPhee F; Hernandez D; Cohen D; Cooney E; Noviello S; Hughes EA
    Gastroenterology; 2015 Feb; 148(2):355-366.e1. PubMed ID: 25311593
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C.
    Forestier N; Reesink HW; Weegink CJ; McNair L; Kieffer TL; Chu HM; Purdy S; Jansen PL; Zeuzem S
    Hepatology; 2007 Sep; 46(3):640-8. PubMed ID: 17879366
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failure.
    Foster GR; Zeuzem S; Andreone P; Pol S; Lawitz EJ; Diago M; Roberts S; Pockros PJ; Younossi Z; Lonjon-Domanec I; De Meyer S; Luo D; George S; Beumont M; Picchio G
    J Hepatol; 2013 Mar; 58(3):488-94. PubMed ID: 23183521
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure.
    Ogawa E; Furusyo N; Dohmen K; Kajiwara E; Kawano A; Nomura H; Takahashi K; Satoh T; Azuma K; Nakamuta M; Koyanagi T; Kotoh K; Shimoda S; Hayashi J;
    J Viral Hepat; 2015 Dec; 22(12):992-1001. PubMed ID: 26075320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.